Ubs Group Ag Zentalis Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 29,528 shares of ZNTL stock, worth $88,584. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,528

Previous 107,100 72.43%

Holding current value

$88,584

Previous $438,000 75.34%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.9 - $4.57 $224,958 - $354,504	-77,572 Reduced 72.43%	29,528 $108,000
Q2 2024 Aug 13, 2024	SELL	$4.09 - $16.13 $657,528 - $2.59 Million	-160,765 Reduced 60.02%	107,100 $438,000
Q1 2024 May 13, 2024	BUY	$10.83 - $16.49 $2.9 Million - $4.42 Million	267,755 Added 243413.64%	267,865 $4.22 Million
Q4 2023 Feb 09, 2024	SELL	$9.84 - $20.13 $656,554 - $1.34 Million	-66,723 Reduced 99.84%	110 $1,000
Q3 2023 Nov 09, 2023	SELL	$19.63 - $28.29 $449,919 - $648,406	-22,920 Reduced 25.54%	66,833 $1.34 Million
Q2 2023 Aug 11, 2023	BUY	$17.41 - $30.05 $110,449 - $190,637	6,344 Added 7.61%	89,753 $2.53 Million
Q1 2023 May 12, 2023	SELL	$16.14 - $24.94 $1.15 Million - $1.78 Million	-71,483 Reduced 46.15%	83,409 $1.43 Million
Q4 2022 Feb 08, 2023	BUY	$18.07 - $25.6 $2.35 Million - $3.33 Million	129,897 Added 519.69%	154,892 $3.12 Million
Q3 2022 Nov 10, 2022	SELL	$20.23 - $31.73 $98,075 - $153,827	-4,848 Reduced 16.25%	24,995 $542,000
Q2 2022 Aug 10, 2022	SELL	$17.91 - $52.25 $795,418 - $2.32 Million	-44,412 Reduced 59.81%	29,843 $839,000
Q1 2022 May 16, 2022	BUY	$41.58 - $80.89 $1.61 Million - $3.13 Million	38,749 Added 109.13%	74,255 $3.43 Million
Q4 2021 Feb 14, 2022	BUY	$66.92 - $84.79 $2.36 Million - $2.99 Million	35,241 Added 13298.49%	35,506 $2.98 Million
Q3 2021 Nov 15, 2021	BUY	$46.83 - $73.5 $468 - $735	10 Added 3.92%	265 $18,000
Q2 2021 Aug 13, 2021	BUY	$37.41 - $62.25 $9,539 - $15,873	255 New	255 $14,000
Q1 2021 May 12, 2021	SELL	$35.69 - $52.72 $6,495 - $9,595	-182 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$31.71 - $57.97 $5,771 - $10,550	182 New	182 $9,000
Q3 2020 Nov 12, 2020	SELL	$27.03 - $47.97 $6,946 - $12,328	-257 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$23.2 - $54.8 $5,962 - $14,083	257 New	257 $12,000

Others Institutions Holding ZNTL

# of Institutions

142

Shares Held

67.9M

Call Options Held

48.5K

Put Options Held

89.6K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account